Horst Rose

Part of VERAXA Biotech GmbH, SYNIMMUNE GmbH is a biotechnology company based in Tuebingen, Germany. The German company is dedicated to developing innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE's lead product candidate is the flt3 specific antibody flysyn, which was recently tested in a first-in-human phase i/ii clinical study in aml patients. The CEOs are Ludger Große-Hovest, Martin Steiner. SYNIMMUNE GmbH was founded in 2010 by Gundram Jung, Hans-Georg Rammensee, Ludger Große-Hovest, Steffen Aulwurm, Andreas Herrmann. SYNIMMUNE was acquired by VERAXA Biotech GmbH on December 29, 2023 for $35.54 million.

Vakzine Projekt Management GmbH develops vaccines and biopharmaceuticals products from laboratory stages through to clinical examination. It offers VPM2001 vaccine to prevent human cytomegalovirus infections and VPM5001 Soluferon vaccine, treatment for multiple sclerosis (MS) and hepatitis C. The company was founded in August 2002 and is headquartered in Hannover, Germany.

Part of Sanofi, Behringwerke AG is a German company that produces specialty chemicals and pharmaceutical products. The company is based in Marburg, Germany.